Logo image of MYGN

MYRIAD GENETICS INC (MYGN) Stock Fundamental Analysis

NASDAQ:MYGN - Nasdaq - US62855J1043 - Common Stock - Currency: USD

14.18  -0.8 (-5.34%)

After market: 14.35 +0.17 (+1.2%)

Fundamental Rating

3

Overall MYGN gets a fundamental rating of 3 out of 10. We evaluated MYGN against 571 industry peers in the Biotechnology industry. MYGN has a bad profitability rating. Also its financial health evaluation is rather negative. MYGN has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year MYGN was profitable.
In the past year MYGN has reported a negative cash flow from operations.
In the past 5 years MYGN reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: MYGN reported negative operating cash flow in multiple years.
MYGN Yearly Net Income VS EBIT VS OCF VS FCFMYGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

1.2 Ratios

With an excellent Return On Assets value of -14.30%, MYGN belongs to the best of the industry, outperforming 83.84% of the companies in the same industry.
MYGN has a better Return On Equity (-20.96%) than 84.55% of its industry peers.
Industry RankSector Rank
ROA -14.3%
ROE -20.96%
ROIC N/A
ROA(3y)-11.46%
ROA(5y)-9.66%
ROE(3y)-16.36%
ROE(5y)-14.08%
ROIC(3y)N/A
ROIC(5y)N/A
MYGN Yearly ROA, ROE, ROICMYGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 -20 -30

1.3 Margins

Looking at the Gross Margin, with a value of 69.06%, MYGN belongs to the top of the industry, outperforming 82.77% of the companies in the same industry.
MYGN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MYGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-2.06%
MYGN Yearly Profit, Operating, Gross MarginsMYGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MYGN has been increased compared to 1 year ago.
MYGN has more shares outstanding than it did 5 years ago.
MYGN has a worse debt/assets ratio than last year.
MYGN Yearly Shares OutstandingMYGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
MYGN Yearly Total Debt VS Total AssetsMYGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

MYGN has an Altman-Z score of 1.94. This is not the best score and indicates that MYGN is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of MYGN (1.94) is better than 70.69% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that MYGN is not too dependend on debt financing.
MYGN's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. MYGN is outperformed by 64.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 1.94
ROIC/WACCN/A
WACC9.51%
MYGN Yearly LT Debt VS Equity VS FCFMYGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 1.96 indicates that MYGN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.96, MYGN is doing worse than 76.91% of the companies in the same industry.
MYGN has a Quick Ratio of 1.78. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.78, MYGN is not doing good in the industry: 77.80% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.78
MYGN Yearly Current Assets VS Current LiabilitesMYGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 131.82% over the past year.
Looking at the last year, MYGN shows a quite strong growth in Revenue. The Revenue has grown by 12.15% in the last year.
The Revenue has been growing slightly by 0.25% on average over the past years.
EPS 1Y (TTM)131.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)12.15%
Revenue growth 3Y5.66%
Revenue growth 5Y0.25%
Sales Q2Q%11.15%

3.2 Future

MYGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.15% yearly.
Based on estimates for the next years, MYGN will show a small growth in Revenue. The Revenue will grow by 7.50% on average per year.
EPS Next Y148.13%
EPS Next 2Y48.4%
EPS Next 3Y46.96%
EPS Next 5Y36.15%
Revenue Next Year11.65%
Revenue Next 2Y7.37%
Revenue Next 3Y7.96%
Revenue Next 5Y7.5%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MYGN Yearly Revenue VS EstimatesMYGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M 1B
MYGN Yearly EPS VS EstimatesMYGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 1 1.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

MYGN is valuated quite expensively with a Price/Earnings ratio of 101.29.
Based on the Price/Earnings ratio, MYGN is valued cheaply inside the industry as 93.07% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 29.62, MYGN is valued quite expensively.
MYGN is valuated quite expensively with a Price/Forward Earnings ratio of 250.35.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MYGN indicates a rather cheap valuation: MYGN is cheaper than 90.59% of the companies listed in the same industry.
MYGN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.70.
Industry RankSector Rank
PE 101.29
Fwd PE 250.35
MYGN Price Earnings VS Forward Price EarningsMYGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200 250

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYGN Per share dataMYGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

MYGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MYGN's earnings are expected to grow with 46.96% in the coming years.
PEG (NY)0.68
PEG (5Y)N/A
EPS Next 2Y48.4%
EPS Next 3Y46.96%

More info and screens

0

5. Dividend

5.1 Amount

MYGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MYRIAD GENETICS INC

NASDAQ:MYGN (2/21/2025, 8:00:01 PM)

After market: 14.35 +0.17 (+1.2%)

14.18

-0.8 (-5.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-24 2025-02-24/amc
Inst Owners104.25%
Inst Owner Change-96.66%
Ins Owners2.21%
Ins Owner Change-0.99%
Market Cap1.29B
Analysts69.09
Price Target19.56 (37.94%)
Short Float %5.46%
Short Ratio4.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)295.74%
Min EPS beat(2)90.66%
Max EPS beat(2)500.81%
EPS beat(4)4
Avg EPS beat(4)215.82%
Min EPS beat(4)63.74%
Max EPS beat(4)500.81%
EPS beat(8)6
Avg EPS beat(8)85.25%
EPS beat(12)10
Avg EPS beat(12)87.36%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.81%
Min Revenue beat(2)1.17%
Max Revenue beat(2)2.44%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)4.97%
Revenue beat(8)5
Avg Revenue beat(8)0.03%
Revenue beat(12)7
Avg Revenue beat(12)0.18%
Revenue beat(16)11
Avg Revenue beat(16)1.86%
PT rev (1m)-11.32%
PT rev (3m)-36.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.66%
EPS NY rev (3m)22.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)-0.22%
Valuation
Industry RankSector Rank
PE 101.29
Fwd PE 250.35
P/S 1.61
P/FCF N/A
P/OCF N/A
P/B 1.74
P/tB 9.58
EV/EBITDA N/A
EPS(TTM)0.14
EY0.99%
EPS(NY)0.06
Fwd EY0.4%
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS8.81
BVpS8.13
TBVpS1.48
PEG (NY)0.68
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.3%
ROE -20.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.06%
FCFM N/A
ROA(3y)-11.46%
ROA(5y)-9.66%
ROE(3y)-16.36%
ROE(5y)-14.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-2.06%
F-Score5
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.83%
Cap/Sales 6.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.96
Quick Ratio 1.78
Altman-Z 1.94
F-Score5
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)77.68%
Cap/Depr(5y)51.8%
Cap/Sales(3y)6.34%
Cap/Sales(5y)4.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)131.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y148.13%
EPS Next 2Y48.4%
EPS Next 3Y46.96%
EPS Next 5Y36.15%
Revenue 1Y (TTM)12.15%
Revenue growth 3Y5.66%
Revenue growth 5Y0.25%
Sales Q2Q%11.15%
Revenue Next Year11.65%
Revenue Next 2Y7.37%
Revenue Next 3Y7.96%
Revenue Next 5Y7.5%
EBIT growth 1Y42.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year226.54%
EBIT Next 3Y62.14%
EBIT Next 5Y49.52%
FCF growth 1Y12.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.59%
OCF growth 3YN/A
OCF growth 5YN/A